Bavarian Nordic: State gains from vaccine support capped by contract

Bavarian Nordic's potential corona vaccine will not be a gold mine investment for the Danish state, the biotech company's CFO says, as their agreement includes a cap on royalties.


After obtaining EUR 108m (DKK 800m) in financial aid from the Danish state, Bavarian Nordic has the opportunity to create a lucrative business before the state wants any of that money back.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs